Volume 4.25 | Jun 28

Mammary Cell News 4.25 June 28, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Beclin 1 and Autophagy Are Required for the Tumorigenicity of Breast Cancer Stem-Like/Progenitor Cells
Scientists demonstrated that a prosurvival autophagic pathway is critical for cancer stem-like cell maintenance, and that Beclin 1 plays a dual role in tumor development. [Oncogene] Full Article

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)
PUBLICATIONS (Ranked by impact factor of the journal)


Control of FLIPL Expression and TRAIL Resistance by the Extracellular Signal-Regulated Kinase1/2 Pathway in Breast Epithelial Cells
Researchers showed that inhibition of epidermal growth factor receptor (EGFR) signaling in non-transformed breast epithelial cells by EGF deprivation or gefitinib causes the upregulation of the long isoform of caspase-8 inhibitor FLICE-inhibitory protein (FLIPL) and makes these cells more resistant to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). [Cell Death Differ] Abstract

Rational Design of Small Molecule Inhibitors Targeting RhoA Subfamily Rho GTPases
Researchers suggest that by suppressing RhoA or RhoC activity, Rhosin could inhibit mammary sphere formation by breast cancer cells, suppress invasion of mammary epithelial cells, and induce neurite outgrowth of PC12 cells in synergy with NGF. [Chem Biol] Abstract | Press Release

Distinct Regulation of Cytoplasmic Calcium Signals and Cell Death Pathways by Different Plasma Membrane Calcium ATPase Isoforms in MDA-MB-231 Breast Cancer Cells
Scientists assessed the impact of plasma membrane calcium ATPase isoform 1 (PMCA1) and PMCA4 silencing on cytoplasmic free Ca2+ signals and cell viability in MDA-MB-231 breast cancer cells. [J Biol Chem] Abstract | Full Article

Stable Inhibition of Specific Estrogen Receptor α (ERα) Phosphorylation Confers Increased Growth, Migration/Invasion, and Disruption of Estradiol Signaling in MCF-7 Breast Cancer Cells
Attenuated phosphorylation of ERα at serines 118 (S118) and S167 significantly affected cellular physiology and behavior in MCF-7 breast cancer cells, resulting in increased growth, migration/invasion, compromised expression of ERα target genes, and markedly altered gene expression patterns. [Endocrinology] Abstract

The Opposite Effects of Doxorubicin on Bone Marrow Stem Cells versus Breast Cancer Stem Cells Depend on Glucosylceramide Synthase
Scientists report that, due to the difference of glucosylceramide synthase, catalyzing ceramide glycosylation, doxorubicin eliminates bone marrow stem cells and expands breast cancer stem cells. [Int J Biochem Cell Biol] Abstract

Measles Virus Selectively Blind to Signaling Lymphocyte Activation Molecule as a Novel Oncolytic Virus for Breast Cancer Treatment
Researchers used reverse genetics to generate a recombinant measles virus selectively unable to use SLAM (rMV-SLAMblind). They showed that, unlike the MV vaccine strains, rMV-SLAMblind used polio virus receptor-related 4 as a receptor to infect breast cancer cells and not the ubiquitously expressed CD46. [Gene Ther] Abstract

Hornerin, an S100 Family Protein, Is Functional in Breast Cells and Aberrantly Expressed in Breast Cancer
Scientists investigated hornerin’s potential role in normal breast cells and breast cancer. [BMC Cancer] Abstract | Full Article


Electrochemotherapy for Large Locoregional Recurrence of Breast Cancer: Results from a Phase II Clinical Trial Showing Efficacy in Heavily Pretreated Patients
This first phase II study indicated that electrochemotherapy is a promising treatment alternative for cutaneous recurrences of breast cancer. [Acta Oncol] Abstract

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients with Metastatic Breast Cancer: Final Analysis of Overall Survival
A randomized phase II study in first-line metastatic breast cancer demonstrated superior efficacy and safety of weekly nab-paclitaxel compared with docetaxel. Final survival analyses and updated safety results were reported. [Clin Breast Cancer] Abstract

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.


CHMP Recommends Novartis Drug Afinitor® for EU Approval Marking Major Milestone in the Treatment of Advanced Breast Cancer
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for Afinitor® (everolimus) tablets, in combination with exemestane, for the treatment of hormone receptor-positive, HER2/neu-negative advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. [Novartis AG] Press Release

New Scottish-Californian Stem Cell Research Announced
Scientists from Heriot-Watt together with their counterparts in St Andrews and Stanford universities are to work together on new medical research that could lead to major breakthroughs for people living with life-threatening conditions. The Heriot-Watt and St Andrews teams will work with research groups at Stanford to examine how stem cells grow and divide and how they change shape to form different types of tissue. [Heriot-Watt University] Press Release

Connexon Creative - Complete our survey and be entered in a draw to win one of 50 Starbucks gift cards!
We care what you think! Please help Connexon Creative improve our newsletters by taking our survey. For responding, you will be entered in a draw to win one of 50 Starbucks gift cards valued at $10 each!* Enter here
*Starbucks promotion only applies where Starbucks gift cards are redeemable. Prizes will be given at random when survey closes.


U.K. Panel Backs Open Access for All Publicly Funded Research Papers
A long-awaited government report in the United Kingdom says open access journals should be “the main vehicle for the publication of research.” But it warns that such a move would cost the United Kingdom more than $80 million per year in publication charges and other costs. [The Working Group on Expanding Access to Published Research Findings, United Kingdom] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Gordon Research Conference: Cancer Genetics & Epigenetics
April 21-26, 2013
Lucca, Italy

our events page to see a complete list of events in the mammary cell community.


Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Assistant Professor – Oncology/Breast Cancer (University of Chicago)

Associate Professor – Metastatic Breast Cancer (University of Colorado Comprehensive Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us